Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.

@article{McKeage2003OctreotideLR,
  title={Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.},
  author={Kate McKeage and Susan M. Cheer and Antona J. Wagstaff},
  journal={Drugs},
  year={2003},
  volume={63 22},
  pages={2473-99}
}
Octreotide long-acting release (LAR) is a somatostatin analogue designed for once monthly intramuscular injection. As with endogenous somatostatin, octreotide LAR inhibits secretion of growth hormone (GH) as well as various other peptide hormones. In the treatment of acromegaly, octreotide LAR effectively controlled the secretion of GH and insulin-like growth factor-1 (IGF-1) in about 55-70% of patients (n > 100) who had previously been treated with somatostatin analogues, a similar degree of… CONTINUE READING
31 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…